About Travecta Therapeutics

About Us

Fundamental Discovery has resulted in Our Revolutionary Platform for Delivering Drugs more Effectively into the Brain.

Travecta Therapeutics develops novel pharmaceutical technologies for the delivery of therapeutic agents to the brain. Travecta has been built upon the research of Dr. David Silver and leverages a key discovery regarding how the brain regulates the transport of molecules to develop a platform to identify, simplify and categorize small molecules for enabling their transport across the blood-brain barrier. contact us

Management Team

Our Team

Prof David L. Silver Scientific Founder

  • Professor and Deputy Director of the Signature Research Program in Cardiovascular & Metabolic Disorders at Duke-NUS Medical School, Singapore.
  • Research focus on molecular nutrition and role of lipids in brain and eye function and health. Discoverer of the Mfsd2a-LPC pathway.
  • Doctorate in Genetics from University of Michigan and postdoctoral training in cardiovascular and lipid research at Columbia University. Held tenure-track faculty appointments at Columbia University and the Albert Einstein College of Medicine, USA.

Dr. Mahmood Ahmed Scientific Founder

  • Drug Discovery and Development expert, with 14 years of Pharma experience, the majority of which has been spent in the CNS field.
  • Established Drug Discovery capability, lead multiple drug discovery projects, developed projects to key milestones, achieving desired outcomes and delivering multiple assets for clinical development.
  • Doctorate in Synthetic Chemistry from Imperial College, joined GSK as a Medicinal Chemist, building in depth knowledge of DMPK, disease biology, and pharmacology. Member of R&D site leadership team.

Dr. Michael Shleifer Founder, Singapore

  • Founder and Managing Partner of SPRIM with 20 year experience in the healthcare sector
  • Co-founder of SPRIM Ventures, which formed TKS1 in partnership with Tikehau Capital, a healthcare and life science focused venture fund
  • Board member in multiple startups
  • Long experience in Pharmaceuticals and Medtech
  • Doctorate from Universite Rene Descartes Paris V and a Master Political Science from Sciences Po Paris

Laurent Benissan Founder, Singapore

  • Co-founder of SPRIM Ventures which formed TKS1 in partnership with Tikehau Capital, a healthcare and life science focused venture fund
  • Founder of Silhouette Lift, an innovative medical device company in the aesthetic field. Started the company in 2007 and developed a cutting edge technology used for minimally invasive facial rejuvenation. In 2014, Silhouette Lift was sold to Sinclair IS Pharma, a public company in the UK.
  • Board member in multiple startups
  • Spent the first 15 years of his career in investment banking, working for Merrill Lynch and other international firms.
  • Master in management from HEC business school in France.